For the quarter ending 2025-09-30, INKT had $12,599,297 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,887,709 | -7,004,448 |
| Depreciation | 43,654 | 99,528 |
| Share-based compensation | 620,585 | 1,487,641 |
| Loss on disposal of assets | -2,188 | -167,103 |
| Change in fair value of related party note | 193,920 | 532,012 |
| Interest accrued on related party note | 25,000 | 49,722 |
| Prepaid expenses | -21,016 | 27,452 |
| Accounts payable | 381,852 | 577,453 |
| Accrued liabilities and other current liabilities | 52,659 | 84,280 |
| Other operating assets and liabilities | -605,487 | -1,124,067 |
| Net cash used in operating activities | -941,348 | -2,910,094 |
| Net proceeds from sale of equity | 13,137,498 | - |
| Proceeds from employee stock purchases and option exercises | 408,180 | 1,116 |
| Net cash provided by financing activities | 13,545,678 | 1,116 |
| Effect of exchange rate changes on cash | -5,033 | 13,853 |
| Net increase in cash and cash equivalents | 12,599,297 | -2,895,125 |
| Cash and cash equivalents at beginning of period | 4,577,040 | - |
| Cash and cash equivalents at end of period | 14,281,212 | - |
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)